Latest Breaking News On - Two part design provides optionality - Page 1 : comparemela.com

/PRNewswire/ NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today.

United statesMichael millerDavid ramirezPrnewswire neurobo pharmaceuticals incRx communications groupNeurobo pharmaceuticalsDonga st coNeurobo pharmaceuticals incTwo part design provides optionalityInterim analysisFirst halfData readout expectedSecond halfG protein coupled receptorSouth texas research institutePrincipal investigator